Results 111 to 120 of about 272,512 (195)

Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).

, 2012
120 Background: NEPC is an aggressive variant of prostate cancer that most commonly arises from prostate adenocarcinoma (PCA), with likely clonal origin. There is currently no effective therapy with most patients surviving < 1 yr.
Scott T. Tagawa, Juan Miguel Mosquera, Himisha Beltran, Mark A. Rubin, Kyung Park, Theresa Macdonald, David M. Nanus   +6 more
core   +1 more source

Neuroblastomas with Discordant Genotype-Phenotype Relationships: Report of Four Cases with MYCN Amplification and Favorable Histology

, 2011
MYCN amplification prevents cellular differentiation and promotes mitotic and karyorrhectic activities in neuroblastomas. Hence, MYCN-amplified tumors typically show an appearance of neuroblastoma of either an undifferentiated or a poorly differentiated
Atsuko Nakagawa, Masaaki Kumagai, Hideto Iwafuchi, Hisanari Hori, Hajime Okita, Kentaro Matsuoka   +5 more
core   +1 more source

Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells. [PDF]

Cancer Sci, 2023
Mukae K, Takenobu H, Endo Y, Haruta M, Shi T, Satoh S, Ohira M, Funato M, Toguchida J, Osafune K, Nakahata T, Kanda H, Kamijo T.   +12 more
europepmc   +1 more source

Letting the breaks off MYCN

, 2016
Much of our understanding of the biology of MYCN amplification in neuroblastoma is based on the exploration of transcriptional activity of MYCN.
MILAZZO, GIORGIO, Narayan, Nisha, PERINI, GIOVANNI, Paul G Ekert, Ekert, Paul G., Giorgio Milazzo, Nisha Narayan, Giovanni Perini   +7 more
core   +1 more source

Correction to “Molecular and clinical features of a Japanese medulloblastoma cohort: Subgroup‐specific prognostic stratification using economical/accessible diagnostic methods”

Brain Pathology, EarlyView.
wiley   +1 more source

Amplification of Mycn, Ddx1, Rrm2 and Odc1 in rat uterine endometrial carcinomas

, 2001
The BDII rat is genetically predisposed to estrogen-dependent endometrial adenocarcinoma and represents a valuable model for this type of tumor. Tumors arising in strain crosses involving the BDII rats had previously been screened for DNA copy number ...
Levan, G., Karlsson, Annika, Walentinsson, A., Helou, Khalil, Hedrich, Hans Jürgen, Szpirer, Claude   +5 more
core   +1 more source

Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology

npj Precision Oncology
A deep learning model using attention-based multiple instance learning (aMIL) and self-supervised learning (SSL) was developed to perform pathologic classification of neuroblastic tumors and assess MYCN-amplification status using H&E-stained whole slide ...
Siddhi Ramesh, Emma Dyer, Monica Pomaville, Kristina Doytcheva, James Dolezal, Sara Kochanny, Rachel Terhaar, Casey J. Mehrhoff, Kritika Patel, Jacob Brewer, Benjamin Kusswurm, Arlene Naranjo, Hiroyuki Shimada, Nicole A. Cipriani, Aliya N. Husain, Peter Pytel, Elizabeth A. Sokol, Susan L. Cohn, Rani E. George, Alexander T. Pearson, Mark A. Applebaum   +20 more
doaj   +1 more source

Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy. [PDF]

Front Pediatr, 2022
Lu XY, Qu LJ, Duan XL, Zuo W, Sai K, Rui G, Gong XF, Ding YB, Gao Q.   +8 more
europepmc   +1 more source

Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas

, 2008
BACKGROUND: Surgery is the first line treatment for low-grade neuroblastomas. In stage I tumors, the presence of MYCN amplification is rarely detected and the Shimada histology is not always taken into consideration when deciding on the treatment.
de Buys Roessingh, A. S., Wiesenauer, C., Bouron-Dal Soglio, D., Rougemont-Pidoux, Anne-Laure, Barrette, S., Lallier, M.   +5 more
core   +1 more source

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report. [PDF]

Clin Cancer Res, 2023
Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S.   +15 more
europepmc   +1 more source